Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775866 | 0.92 | FGFR4 (0.45) | FGFR4NPY5RKMO | |
| SCHEMBL16775850 | 0.91 | FGFR4 (0.44) | FGFR4GRM5NPY5RKMO | |
| SCHEMBL16775857 | 0.88 | FGFR4 (0.44) | FGFR4GRM5KMOALDH1A1MEN1 | |
| SCHEMBL16776004 | 0.88 | FGFR4 (0.42) | FGFR4GRM5ALDH1A1MAPT | |
| SCHEMBL16776049 | 0.88 | FGFR4 (0.42) | FGFR4CNR1 | |
| SCHEMBL16775825 | 0.88 | CNR2 (0.53) | FGFR4CNR2GRM5CNR1KMO | |
| SCHEMBL16775913 | 0.86 | MPL (0.42) | CNR2GRM5CNR1KMOALDH1A1 | |
| SCHEMBL16775847 | 0.86 | FGFR4 (0.43) | FGFR4GRM5KMOALDH1A1MEN1 | |
| SCHEMBL16776021 | 0.86 | FGFR4 (0.42) | FGFR4 | |
| SCHEMBL16776040 | 0.85 | FGFR4 (0.41) | FGFR4GRM5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FGFR4 1754/4885CNR2 2514/4885GRM5 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.